HomeCompareYNDX vs ABBV

YNDX vs ABBV: Dividend Comparison 2026

YNDX yields 10.56% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $62.1K in total portfolio value· pulled ahead in Year 4
10 years
YNDX
YNDX
● Live price
10.56%
Share price
$18.94
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.2K
Annual income
$2,047.72
Full YNDX calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — YNDX vs ABBV

📍 ABBV pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodYNDXABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, YNDX + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
YNDX pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

YNDX
Annual income on $10K today (after 15% tax)
$897.57/yr
After 10yr DRIP, annual income (after tax)
$1,740.56/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $19,315.44/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of YNDX + ABBV for your $10,000?

YNDX: 50%ABBV: 50%
100% ABBV50/50100% YNDX
Portfolio after 10yr
$71.3K
Annual income
$13,409.74/yr
Blended yield
18.82%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

YNDX
Analyst Ratings
20
Buy
3
Hold
2
Sell
Consensus: Buy
Price Target
$79.00
+317.1% upside vs current
Range: $79.00 — $79.00
Altman Z
9188.3
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

YNDX buys
4
ABBV buys
0
PoliticianChamberTickerTypeAmountDate
Ro Khanna🏢 House$YNDX▼ Sell$1,001 - $15,0002023-06-15
Ro Khanna🏢 House$YNDX▲ Buy$1,001 - $15,0002022-02-14
Ro Khanna🏢 House$YNDX▲ Buy$1,001 - $15,0002022-01-21
Peter Meijer🏢 House$YNDX▼ Sell$1,001 - $15,0002021-02-17
Greg Gianforte🏢 House$YNDX▼ Sell$100,001 - $250,0002020-10-08
Josh Gottheimer🏢 House$YNDX▼ Sell$1,001 - $15,0002020-10-06
Greg Gianforte🏢 House$YNDX▲ Buy$15,001 - $50,0002020-01-13
Greg Gianforte🏢 House$YNDX▼ Sell$15,001 - $50,0002020-01-03
Donna Shalala🏢 House$YNDX▼ Sell$1,001 - $15,0002019-06-24
Greg Gianforte🏢 House$YNDX▲ Buy$15,001 - $50,0002019-04-24
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricYNDXABBV
Forward yield10.56%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$40.2K$102.3K
Annual income after 10y$2,047.72$24,771.77
Total dividends collected$15.5K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy
Analyst price target$79.00$256.15

Year-by-year: YNDX vs ABBV ($10,000, DRIP)

YearYNDX PortfolioYNDX Income/yrABBV PortfolioABBV Income/yrGap
1$11,756$1,055.97$11,550$430.00+$206.00YNDX
2$13,739$1,160.18$13,472$627.96+$267.00YNDX
3$15,968$1,267.18$15,906$926.08+$62.00YNDX
4← crossover$18,462$1,376.41$19,071$1,382.55$609.00ABBV
5$21,242$1,487.30$23,302$2,095.81$2.1KABBV
6$24,328$1,599.27$29,150$3,237.93$4.8KABBV
7$27,743$1,711.80$37,536$5,121.41$9.8KABBV
8$31,509$1,824.37$50,079$8,338.38$18.6KABBV
9$35,651$1,936.49$69,753$14,065.80$34.1KABBV
10$40,195$2,047.72$102,337$24,771.77$62.1KABBV

YNDX vs ABBV: Complete Analysis 2026

YNDXStock

Yandex N.V., a technology company, builds intelligent products and services powered by machine learning and other technologies to help consumers and businesses navigate the online and offline world. The company operates through Search and Portal, Taxi, Yandex.Market, Media Services, Classifieds, and Other Business Units and Initiatives segments. It provides locally relevant search and information services. The company also develops on-demand transportation, delivery, and navigation services and products, as well as operates in the e-commerce, online entertainment, and cloud computing markets to address the needs of customers in Russia and various international markets. In addition, it operates Yandex.Plus, a subscription loyalty program; offers fintech instruments, such as payment and financial services; and advertising services. Further, the company operates classifieds platforms for the sale of used and new cars, motorcycles, commercial vehicles, and spare parts; and sale and rental of apartments, houses, and commercial property for private individuals, developers, and realtors, as well as a long-term apartment rental platform to manage pre-contract rental processes and subsequent administration of the payments. Additionally, it operates Yandex Zen, a social infotainment platform that brings together content creators and users; and Yandex Cloud, a cloud platform that provides infrastructure, storage, machine learning, and development tools to build and enhance cutting-edge digital services and applications for B2B customers and individual developers. The company was founded in 1989 and is based in Schiphol, the Netherlands.

Full YNDX Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this YNDX vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

YNDX vs SCHDYNDX vs JEPIYNDX vs OYNDX vs KOYNDX vs MAINYNDX vs JNJYNDX vs MRKYNDX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.